← Back to headlines
Roivant Shares Rise Following Positive Immunovant Trial Data
Roivant Sciences experienced gains in its stock value after positive mid-stage trial data was released for Immunovant’s primary asset.
20 May, 14:10 — 20 May, 14:10
Sources
Showing 1 of 1 sources
